Sanofi Withdraws Zimulti NDA For Weight Loss
This article was originally published in The Pink Sheet Daily
Executive SummaryCompany cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.
You may also be interested in...
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.